Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Rating Lowered by Wall Street Zen

Syndax Pharmaceuticals (NASDAQ:SNDX) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

A number of other analysts have also recently weighed in on SNDX. BTIG Research restated a “buy” rating and set a $56.00 target price on shares of Syndax Pharmaceuticals in a report on Tuesday, December 9th. UBS Group raised their price objective on Syndax Pharmaceuticals from $35.00 to $38.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Syndax Pharmaceuticals in a report on Monday, December 29th. Barclays upped their target price on Syndax Pharmaceuticals from $22.00 to $35.00 and gave the company an “overweight” rating in a report on Monday, November 24th. Finally, Stifel Nicolaus set a $45.00 price target on Syndax Pharmaceuticals in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Syndax Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $37.30.

Syndax Pharmaceuticals Price Performance

Shares of Syndax Pharmaceuticals stock opened at $21.71 on Friday. The company has a current ratio of 4.64, a quick ratio of 4.42 and a debt-to-equity ratio of 2.78. The company’s 50-day moving average price is $20.86 and its two-hundred day moving average price is $18.06. Syndax Pharmaceuticals has a 52 week low of $8.58 and a 52 week high of $22.73. The stock has a market cap of $1.91 billion, a PE ratio of -6.60 and a beta of 0.42.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.14). Syndax Pharmaceuticals had a negative net margin of 165.37% and a negative return on equity of 175.50%. The business had revenue of $68.73 million for the quarter, compared to the consensus estimate of $64.75 million. During the same quarter last year, the business posted ($1.10) EPS. The business’s revenue for the quarter was up 792.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Syndax Pharmaceuticals will post -3.72 EPS for the current fiscal year.

Insider Buying and Selling at Syndax Pharmaceuticals

In related news, CFO Keith A. Goldan sold 3,410 shares of the stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $21.03, for a total value of $71,712.30. Following the completion of the sale, the chief financial officer directly owned 140,429 shares of the company’s stock, valued at approximately $2,953,221.87. This represents a 2.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Michael A. Metzger sold 17,159 shares of the firm’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $21.03, for a total value of $360,853.77. Following the sale, the chief executive officer owned 491,690 shares of the company’s stock, valued at $10,340,240.70. The trade was a 3.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 30,063 shares of company stock valued at $628,332. 4.10% of the stock is currently owned by insiders.

Institutional Trading of Syndax Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Pallas Capital Advisors LLC boosted its holdings in shares of Syndax Pharmaceuticals by 8.7% during the fourth quarter. Pallas Capital Advisors LLC now owns 10,985 shares of the company’s stock worth $231,000 after purchasing an additional 875 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Syndax Pharmaceuticals by 26.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,223 shares of the company’s stock valued at $89,000 after buying an additional 893 shares during the period. Schroder Investment Management Group lifted its position in Syndax Pharmaceuticals by 1.0% in the 3rd quarter. Schroder Investment Management Group now owns 123,404 shares of the company’s stock worth $1,920,000 after buying an additional 1,241 shares in the last quarter. Verition Fund Management LLC boosted its stake in shares of Syndax Pharmaceuticals by 7.5% during the 4th quarter. Verition Fund Management LLC now owns 18,460 shares of the company’s stock valued at $388,000 after buying an additional 1,281 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its holdings in shares of Syndax Pharmaceuticals by 9.0% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 17,562 shares of the company’s stock valued at $374,000 after acquiring an additional 1,455 shares in the last quarter.

Key Syndax Pharmaceuticals News

Here are the key news stories impacting Syndax Pharmaceuticals this week:

• Positive Sentiment: Robust commercial revenue — Syndax reported $68.7M in Q425 and $172.4M for FY2025, driven by product sales; Revuforj (revumenib) net revenue was $44.2M in Q4 (up 38% vs Q3) and Niktimvo (axatilimab‑csfr) net revenue was $56.0M in Q4 (up 22% vs Q3). Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Revenue topped expectations and showed large year‑over‑year growth (Q4 revenue up ~792% YoY), which investors may view as validation of the commercialization ramp. Syndax Pharmaceuticals Inc (SNDX) Q4 2025 Earnings Call Highlights
• Positive Sentiment: Clinical progress: enrollment completed in the Phase 2 IPF trial of axatilimab with topline data expected in 4Q26 — a clear near‑to‑mid‑term catalyst to monitor. Syndax Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Analyst consensus remains constructive — the stock carries an average rating of “Moderate Buy,” which may support sentiment but is not a new catalyst by itself. Syndax Pharmaceuticals, Inc. Receives Average Rating of “Moderate Buy” from Analysts
• Neutral Sentiment: Company hosted an earnings conference call and published slides; these materials provide additional detail on commercialization cadence and guidance drivers. View Press Release / Slide Deck
• Negative Sentiment: EPS missed estimates — Syndax reported a Q4 loss of $0.78 per share versus consensus around ($0.64)–($0.66), signaling continued losses and pressure on near‑term profitability. Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Tops Revenue Estimates
• Negative Sentiment: Profitability metrics remain weak — the company reported a negative net margin and negative return on equity, underscoring that top‑line growth has yet to translate into earnings. Syndax Q4 Earnings Snapshot / Conference Call

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.